Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05811351 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 305
- Enrollment target
NCT05811351 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 305 participants.
The verdict
NCT05811351, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 305 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.
Interventions
- OTHER Placebo
- DRUG Prednisone
- DRUG JNJ-81201887
- OTHER Sham Procedure
- DRUG Triamcinolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 305 participants |
| Start Date | 2023-03-06 |
| Est. Completion | 2026-02-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05811351
The ClinicalTrials.gov registry entry for NCT05811351 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 305 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT05811351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05811351 about?
NCT05811351 is a clinical study titled "A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)". The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.
What is the current status of trial NCT05811351?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 305 participants. The study started on 2023-03-06. Estimated completion is 2026-02-23.
What interventions are being tested in trial NCT05811351?
The interventions under investigation include: Placebo (OTHER), Prednisone (DRUG), JNJ-81201887 (DRUG), Sham Procedure (OTHER), Triamcinolone (DRUG).
Who is sponsoring clinical trial NCT05811351?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.